Ulimorelin Study of Efficacy and Safety (ULISES 007)

Post-operative administration of ulimorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial large bowel resection.

Lead sponsor: Tranzyme, Inc.•23 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Related studies

COMPLETEDPhase 3

Ulimorelin Study of Efficacy and Safety (ULISES 008)

NCT01296620 · Gastrointestinal Dysmotility

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 26, 2012Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE3

Enrollment332

Start dateJan 2011

Last updatedJul 26, 2012

Condition

Gastrointestinal Dysmotility

Locations shown

Fountain Valley Regional Hospital

Fountain Valley, California

Orange Coast Memorial Med. Ctr.

Fountain Valley, California

USC, Colorectal Surgery Division

Los Angeles, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 26, 2012Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions